Lamivudine + Zidovudine



Combined with:

Indications and Reactions:

Role Indications Reactions
Primary
Hiv Infection 61.3%
Antiretroviral Therapy 8.8%
Acquired Immunodeficiency Syndrome 6.9%
Prophylaxis Against Hiv Infection 5.1%
Antiviral Treatment 4.6%
Antiviral Prophylaxis 2.3%
Drug Use For Unknown Indication 2.3%
Viral Infection 2.3%
Bacteriuria 0.9%
Nausea 0.9%
Pregnancy 0.9%
Urinary Tract Infection 0.9%
Fatigue 0.5%
Hypertension 0.5%
Hypotension 0.5%
Product Used For Unknown Indication 0.5%
Supplementation Therapy 0.5%
Tuberculosis 0.5%
Stillbirth 16.4%
Drug Exposure During Pregnancy 11.5%
Maternal Exposure During Pregnancy 9.8%
Ventricular Septal Defect 8.2%
Congenital Anomaly 4.9%
Premature Baby 4.9%
Vomiting 4.9%
Abortion Spontaneous 3.3%
Cryptorchism 3.3%
Exposure During Pregnancy 3.3%
Foetal Exposure During Pregnancy 3.3%
Gastroschisis 3.3%
Intra-uterine Death 3.3%
Lactic Acidosis 3.3%
Pyelocaliectasis 3.3%
Respiratory Disorder 3.3%
Thrombosis 3.3%
Weight Decreased 3.3%
Anaemia 1.6%
Bradycardia 1.6%
Secondary
Drug Exposure During Pregnancy 30.1%
Hiv Infection 29.6%
Drug Use For Unknown Indication 14.3%
Antiretroviral Therapy 5.7%
Product Used For Unknown Indication 3.3%
Acquired Immunodeficiency Syndrome 3.0%
Antiviral Treatment 2.4%
Hiv Test Positive 1.7%
Systemic Antiviral Treatment 1.6%
Prophylaxis Against Hiv Infection 1.6%
Maternal Exposure Timing Unspecified 1.0%
Antifungal Prophylaxis 0.9%
Prophylaxis 0.8%
Mycobacterium Avium Complex Infection 0.7%
Tuberculosis 0.7%
Disseminated Tuberculosis 0.6%
General Anaesthesia 0.6%
Diarrhoea 0.5%
Trigeminal Neuralgia 0.5%
Neuropathy Peripheral 0.5%
Drug Exposure During Pregnancy 14.8%
Premature Baby 11.6%
Stillbirth 9.5%
Pregnancy 8.0%
Abortion Spontaneous 7.4%
Abortion Induced 6.5%
Ventricular Septal Defect 6.5%
Polydactyly 5.0%
Small For Dates Baby 4.5%
Trisomy 21 3.9%
Talipes 3.0%
Renal Failure 2.4%
Urine Amphetamine Positive 2.4%
Vanishing Bile Duct Syndrome 2.4%
Cryptorchism 2.1%
Hydrocephalus 2.1%
Respiratory Distress 2.1%
Vomiting 2.1%
White Blood Cell Count Decreased 2.1%
Maternal Drugs Affecting Foetus 1.8%
Concomitant
Hiv Infection 44.3%
Drug Use For Unknown Indication 17.9%
Prophylaxis 5.5%
Prophylaxis Against Hiv Infection 5.0%
Product Used For Unknown Indication 4.1%
Drug Hypersensitivity 3.2%
Human Immunodeficiency Virus Transmission 3.0%
Drug Exposure During Pregnancy 2.6%
Maternal Exposure During Pregnancy 2.1%
Antifungal Prophylaxis 1.7%
Maternal Exposure Timing Unspecified 1.4%
Routine Health Maintenance 1.4%
Cough 1.2%
Hiv Test Positive 1.2%
Headache 1.0%
Hypertension 1.0%
Antiretroviral Therapy 0.9%
Depression 0.9%
Diarrhoea 0.9%
Arthralgia 0.8%
Abortion Spontaneous 12.5%
Vomiting 11.4%
Intra-uterine Death 10.8%
Stillbirth 7.4%
Pre-eclampsia 5.7%
Pancytopenia 5.1%
Haemolytic Anaemia 4.5%
Abortion Incomplete 4.0%
Transaminases Increased 4.0%
Trisomy 21 4.0%
Anaemia 3.4%
Premature Baby 3.4%
Pyrexia 3.4%
Vaginal Haemorrhage 3.4%
Death 2.8%
Foetal Exposure During Pregnancy 2.8%
Nausea 2.8%
Pregnancy 2.8%
Premature Rupture Of Membranes 2.8%
Pulmonary Tuberculosis 2.8%
Interacting
Hiv Infection 61.5%
Hepatitis C Virus 23.1%
Drug Use For Unknown Indication 15.4%
Lipodystrophy Acquired 50.0%
Polyneuropathy 50.0%